GA-ASI Begins Demonstration Flights in Greece
10.12.2019 08:00:00 EET | Business Wire | Press release
Today General Atomics Aeronautical Systems, Inc. (GA-ASI) begins a series of demonstration flights using its MQ-9 Guardian Remotely Piloted Aircraft (RPA). The flights, being hosted by the Hellenic Air Force (HAF) and staged out of Larissa Air Base in Greece, showcase the maritime surveillance capabilities of the MQ-9, as well as the GA-ASI-developed Detect and Avoid (DAA) system.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191209005846/en/
GA-ASI's MQ-9 Guardian RPA at the Larissa Air Base in Greece ready to demonstrate maritime surveillance and Detect and Avoid (DAA) capabilities. (Photo: Business Wire)
“We appreciate the HAF’s support with our customer demonstrations,” said Linden Blue, CEO, GA-ASI. “GA-ASI is highlighting the maritime surveillance and civil airspace integration capabilities of our unmanned aircraft for our European customers. Our long-endurance RPA (25-40 hours per sortie, depending on configuration) will be on display and provide insight into the importance of maritime patrol, as well as showcase our DAA avionics system that will support our goal of flying RPA in civil airspace.”
The flight series is being performed for an audience of European country representatives.
“The HAF looks forward to seeing the results of this demonstration. In addition to defense capabilities, these aircraft provide maritime patrol and EEZ monitoring, border surveillance, support for search and rescue efforts, and over-watch of forest fire response efforts,” said an HAF official.
GA-ASI’s DAA system consists of an air-to-air radar integrated with Traffic Alert and Collision Avoidance System (TCAS II) and Automatic Dependent Surveillance-Broadcast (ADS-B). The system’s traffic surveillance and collision avoidance radar provides important safety features for the flight of a large Unmanned Aircraft Systems in controlled airspace.
The MQ-9 will also demonstrate a multi-mode maritime surface-search radar with Inverse Synthetic Aperture Radar (ISAR) mode, an Automatic Identification System (AIS) receiver, and High-Definition/Full-Motion Video sensor equipped with optical and infrared cameras. This sensor suite enables real-time detection and identification of surface vessels over thousands of square nautical miles. The featured Raytheon SeaVue surface-search radar provides continuous tracking of maritime targets and correlation of AIS transmitters with radar tracks.
GA-ASI is also partnering with SES, a leading satellite communications (SATCOM) operator and managed services provider, with over 70 satellites in Geostationary Orbit (GEO) and Medium Earth Orbit (MEO). SES will provide the GEO satellite connectivity that enables the MQ-9 to operate securely with a high capacity datalink, enabling real-time transmission of sensor data from the aircraft, and extending its effective operational range far beyond that of “line-of-sight” datalinks.
“With our global satellite fleet, SES has been supporting the critical needs of GA-ASI and their government customers who have operated these aircraft for close to two decades,” said Nicole Robinson, Senior Vice President, Global Government at SES Networks. “We are proud to support this demonstration effort for the Hellenic Air Force as part of our long-standing relationship with General Atomics.”
Hi-resolution images of MQ-9 Guardian are available to qualified media outlets from the GA-ASI and HAF media contact list. To follow events from the demo, go to ga-asi.com/European-Maritime-Demo.
About GA-ASI
General Atomics Aeronautical Systems, Inc. (GA-ASI), an affiliate of General Atomics, is a leading designer and manufacturer of proven, reliable Remotely Piloted Aircraft (RPA) systems, radars, and electro-optic and related mission systems, including the Predator® RPA series and the Lynx® Multi-mode Radar. With more than six million flight hours, GA-ASI provides long-endurance, mission-capable aircraft with integrated sensor and data link systems required to deliver persistent flight that enables situational awareness and rapid strike. The company also produces a variety of ground control stations and sensor control/image analysis software, offers pilot training and support services, and develops meta-material antennas. For more information, visit ga-asi.com.
Predator and Lynx are registered trademarks of General Atomics Aeronautical Systems, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191209005846/en/
Contact information
Steven Henden
General Atomics Aeronautical Systems, Inc.
+1 (858) 524-8101
ASI-MediaRelations@ga-asi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 15:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. The oral presentation of these data is taking place at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 – June 2, 2026, in Chicago (Abstract #LBA7000. Session: Oral Abstract Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia. May 30, 4:00 – 7:00 p.m. ET [3:00 – 6:00 p.m.
Fortegra Completes Acquisition by DB Insurance29.5.2026 23:30:00 EEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 23:01:00 EEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom